DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Nitric Oxide (Inhaled)

Phase Two

Phase Two

Therapeutic Approach

Anti-Infective

Nitric oxide is a gas with antimicrobial properties that may reduce lung infections when inhaled, leading to improved lung function in people with CF.

Status

A phase 2 study to test the safety and effectiveness of inhaled nitric oxide in adults with CF will begin soon.

Sponsor

This program is sponsored by Novoteris and partially funded by Cystic Fibrosis Foundation Therapeutics (CFFT). It is being conducted within the Cystic Fibrosis Foundation's Therapeutics Development Network.

Contact us about Nitric Oxide (Inhaled) >